- Home
- DHR vs AZN Comparison
DHR vs AZN Comparison
Compare DHR & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | AZN |
|---|---|---|
| Founded | 1969 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7B | 285.7B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | DHR | AZN |
|---|---|---|
| Price | $186.93 | $189.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $250.56 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | 0.69% | ★ 1.66% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.05 | N/A |
| Revenue | ★ $19,893,000,000.00 | N/A |
| Revenue This Year | $5.34 | $10.13 |
| Revenue Next Year | $5.84 | $6.21 |
| P/E Ratio | $37.01 | ★ $31.91 |
| Revenue Growth | ★ 8.53 | N/A |
| 52 Week Low | $171.00 | $61.24 |
| 52 Week High | $242.80 | $212.71 |
Technical Indicators
Market Signals| Indicator | DHR | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 23.50 | 54.67 |
| Support Level | $186.18 | $89.28 |
| Resistance Level | $206.93 | $211.32 |
| Average True Range (ATR) | 4.12 | 3.22 |
| MACD | -1.36 | -5.15 |
| Stochastic Oscillator | 6.58 | 1.66 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.